目的 评价地舒单抗治疗骨质疏松性骨折相关疾病的有效性、安全性和经济性.方法 系统检索2019年1月至2024年5月中国知网、维普网、万方、SinoMed、PubMed、Web of Science、Cochrane Library数据库中关于地舒单抗治疗骨质疏松性骨折随机对照试验研究文献,对纳入的文献进行系统评价.结果 地舒单抗能够减少骨折风险,特别是髋部骨折,同时展现出对提升骨密度的效果.然而,使用地舒单抗的过程中也观察到一些不良反应,包括流感样反应和低钙血症等.在经济性方面,地舒单抗展现出较为理想的特性,但关于其长期疗效和安全性仍需进行深入研究.结论 地舒单抗是治疗骨质疏松性骨折的一种有效药物,但在临床应用时需谨慎关注其潜在的不良反应和经济负担.
Systematic evaluation of denosumab for treatment of osteoporotic fractures
Objective To evaluate the efficacy,safety and economics of denosumab in the treatment of diseases associated with osteoporotic fractures.Methods A systematic search was conducted on databases of CNKI,Weipu,Wanfang and,SinoMed in China from January 2019 to May 2024.PubMed,Web of science and Cochrance Library databases were randomly searched for denosumab in the treatment of osteoporotic fractures.Controlled trials were conducted to study the literaure,and the included literature was systematically reviewed.Results Denosumab significantly reduced the risk of fractures(especially hip fracture)and exerted a significant effect on bone mineral density.However,some adverse effects including influenza-like reactions and hypocalcemia have been observed for denosumab.In terms of economics,denosumab demonstrated a desirable profile.However,further studies are needed to determine its long-term efficacy and safety.Conclusion Denosumab is an effective drug for the treatment of osteoporotic fractures,but its potential adverse effects and economic burden should be carefully paid attention to in clinical use.
NETL
NSTL
万方数据
